Oramed Pharm (OJU1) AI Stock Analysis

Top Page

Oramed Pharm

(Frankfurt:OJU1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Conservative balance sheetExtremely low leverage and a sizable equity base give Oramed financial flexibility relative to more indebted biotechnology peers. This reduces solvency pressure and preserves capacity to support development activities while the company works toward establishing sustainable operating performance.

Negative Factors

Minimal and inconsistent revenueLimited or zero revenue indicates that Oramed has not yet established a durable commercial operating base. This leaves financial performance dependent on development progress and future product success, while restricting internally generated resources available to fund ongoing activities.

Oramed Pharm (OJU1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 170.97M
Dividend Yield: ―
Average Volume (3M): 479
Price to Earnings (P/E): 1.0
Beta (1Y): 0.55
Revenue Growth: -100.00%
EPS Growth: ―
Country: Germany
Employees: 13
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypep...

Oramed Pharm Risk Analysis

Oramed Pharm disclosed 42 risk factors in its most recent earnings report. Oramed Pharm reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Oramed Pharm Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:OJU1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WHWK	44Neutral	$184.71M	-2.89	-53.89%	―	-100.00%	-1813.57%
ALXO	39Underperform	$168.70M	-1.08	-90.30%	―	―	48.20%
SPRB	31Underperform	$133.33M	-1.14	-123.53%	―	-100.00%	52.43%

* Healthcare Sector Average

Performance Comparison

DE:OJU1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:OJU1	Oramed Pharmaceuticals Inc	3.73	1.85	98.35%
WHWK	Whitehawk Therapeutics, Inc.	3.24	1.02	45.95%
ALXO	Alx Oncology Holdings, Inc.	1.22	-0.35	-22.29%
SPRB	Spruce Biosciences, Inc.	46.39	-58.36	-55.71%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Oramed Pharm AI Stock Analysis